Insulin pump therapy, rtCGM, and the use of both treatment modalities significantly increase the mean diabetes-associated costs when compared to no technology users (mean € 2,418, median €1,506, IQR 808—2,702). The gene discussed is INS; the disease is diabetes mellitus.